The European Commission’s forthcoming Pharmaceutical Strategy could help stop advanced therapy medicinal product (ATMP) development moving away from the EU if it removes obstacles that impede access to and development of such products, says the Alliance for Regenerative Medicines
“We really want to ensure that Europe remains a leader in ATMPs, but it has to pay attention to these key areas